# EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

> **NCT04960202** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 2091 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** PF-07321332
- **DRUG:** Ritonavir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04960202
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-16
- **Primary completion:** 2021-12-09
- **Final completion:** 2022-04-25
- **Target enrollment:** 2091 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04960202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04960202, "EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04960202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*